nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—skin cancer—melanoma	0.443	1	CtDrD
Vemurafenib—BRAF—melanoma	0.224	0.838	CbGaD
Vemurafenib—ABCC1—Dactinomycin—melanoma	0.0465	0.26	CbGbCtD
Vemurafenib—ALB—melanoma	0.0435	0.162	CbGaD
Vemurafenib—ABCG2—Dactinomycin—melanoma	0.0311	0.174	CbGbCtD
Vemurafenib—CYP1A2—Carmustine—melanoma	0.0244	0.137	CbGbCtD
Vemurafenib—ABCC1—Docetaxel—melanoma	0.024	0.134	CbGbCtD
Vemurafenib—CYP3A4—Temozolomide—melanoma	0.0185	0.103	CbGbCtD
Vemurafenib—ABCG2—Docetaxel—melanoma	0.0161	0.0898	CbGbCtD
Vemurafenib—CYP1A2—Dacarbazine—melanoma	0.0148	0.0827	CbGbCtD
Vemurafenib—CYP3A4—Docetaxel—melanoma	0.00347	0.0194	CbGbCtD
Vemurafenib—Hyperkeratosis—Bleomycin—melanoma	0.0013	0.052	CcSEcCtD
Vemurafenib—VIIth nerve paralysis—Carmustine—melanoma	0.000792	0.0316	CcSEcCtD
Vemurafenib—Folliculitis—Dactinomycin—melanoma	0.000553	0.0221	CcSEcCtD
Vemurafenib—Rash generalised—Docetaxel—melanoma	0.000491	0.0196	CcSEcCtD
Vemurafenib—Cyst—Carmustine—melanoma	0.000486	0.0194	CcSEcCtD
Vemurafenib—Hepatotoxicity—Dactinomycin—melanoma	0.00045	0.018	CcSEcCtD
Vemurafenib—Hepatotoxicity—Carmustine—melanoma	0.000421	0.0168	CcSEcCtD
Vemurafenib—Hepatotoxicity—Temozolomide—melanoma	0.000407	0.0162	CcSEcCtD
Vemurafenib—Rigors—Temozolomide—melanoma	0.000385	0.0154	CcSEcCtD
Vemurafenib—Gamma-glutamyltransferase increased—Temozolomide—melanoma	0.000382	0.0152	CcSEcCtD
Vemurafenib—Polyp—Docetaxel—melanoma	0.000343	0.0137	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Temozolomide—melanoma	0.000318	0.0127	CcSEcCtD
Vemurafenib—Cyst—Docetaxel—melanoma	0.000313	0.0125	CcSEcCtD
Vemurafenib—Neoplasm—Carmustine—melanoma	0.000294	0.0117	CcSEcCtD
Vemurafenib—Neoplasm—Temozolomide—melanoma	0.000284	0.0113	CcSEcCtD
Vemurafenib—Arthritis—Bleomycin—melanoma	0.000278	0.0111	CcSEcCtD
Vemurafenib—Hepatotoxicity—Docetaxel—melanoma	0.000271	0.0108	CcSEcCtD
Vemurafenib—Rigors—Docetaxel—melanoma	0.000256	0.0102	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.000227	0.00907	CcSEcCtD
Vemurafenib—Etoricoxib—PTGS2—melanoma	0.000224	1	CrCbGaD
Vemurafenib—Weight decreased—Bleomycin—melanoma	0.000211	0.00844	CcSEcCtD
Vemurafenib—Dry skin—Temozolomide—melanoma	0.000209	0.00835	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000205	0.0082	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000193	0.00769	CcSEcCtD
Vemurafenib—Neoplasm—Docetaxel—melanoma	0.000189	0.00754	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Temozolomide—melanoma	0.00018	0.00718	CcSEcCtD
Vemurafenib—Weight decreased—Temozolomide—melanoma	0.000178	0.00712	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Carmustine—melanoma	0.000178	0.00712	CcSEcCtD
Vemurafenib—Infestation NOS—Temozolomide—melanoma	0.000176	0.00702	CcSEcCtD
Vemurafenib—Infestation—Temozolomide—melanoma	0.000176	0.00702	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000174	0.00696	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Temozolomide—melanoma	0.000172	0.00688	CcSEcCtD
Vemurafenib—Chills—Bleomycin—melanoma	0.000168	0.0067	CcSEcCtD
Vemurafenib—Alopecia—Bleomycin—melanoma	0.000165	0.0066	CcSEcCtD
Vemurafenib—Erythema multiforme—Dactinomycin—melanoma	0.000165	0.00659	CcSEcCtD
Vemurafenib—Erythema—Bleomycin—melanoma	0.000163	0.0065	CcSEcCtD
Vemurafenib—Oedema peripheral—Carmustine—melanoma	0.000161	0.00642	CcSEcCtD
Vemurafenib—Connective tissue disorder—Carmustine—melanoma	0.00016	0.00641	CcSEcCtD
Vemurafenib—Atrial fibrillation—Docetaxel—melanoma	0.00016	0.00639	CcSEcCtD
Vemurafenib—Chills—Dactinomycin—melanoma	0.000157	0.00625	CcSEcCtD
Vemurafenib—Oedema peripheral—Temozolomide—melanoma	0.000155	0.00621	CcSEcCtD
Vemurafenib—Connective tissue disorder—Temozolomide—melanoma	0.000155	0.00619	CcSEcCtD
Vemurafenib—Alopecia—Dactinomycin—melanoma	0.000154	0.00615	CcSEcCtD
Vemurafenib—Eye disorder—Carmustine—melanoma	0.000153	0.00609	CcSEcCtD
Vemurafenib—Erythema—Dactinomycin—melanoma	0.000152	0.00606	CcSEcCtD
Vemurafenib—Pain in extremity—Docetaxel—melanoma	0.000152	0.00606	CcSEcCtD
Vemurafenib—Erythema multiforme—Temozolomide—melanoma	0.000149	0.00596	CcSEcCtD
Vemurafenib—Eye disorder—Temozolomide—melanoma	0.000147	0.00589	CcSEcCtD
Vemurafenib—Cardiac disorder—Temozolomide—melanoma	0.000146	0.00585	CcSEcCtD
Vemurafenib—Alopecia—Carmustine—melanoma	0.000144	0.00576	CcSEcCtD
Vemurafenib—Angiopathy—Temozolomide—melanoma	0.000143	0.00572	CcSEcCtD
Vemurafenib—Mediastinal disorder—Temozolomide—melanoma	0.000142	0.00568	CcSEcCtD
Vemurafenib—Erythema—Carmustine—melanoma	0.000142	0.00567	CcSEcCtD
Vemurafenib—Malnutrition—Carmustine—melanoma	0.000142	0.00567	CcSEcCtD
Vemurafenib—Cough—Bleomycin—melanoma	0.000142	0.00567	CcSEcCtD
Vemurafenib—Chills—Temozolomide—melanoma	0.000142	0.00565	CcSEcCtD
Vemurafenib—Alopecia—Temozolomide—melanoma	0.000139	0.00557	CcSEcCtD
Vemurafenib—Dry skin—Docetaxel—melanoma	0.000139	0.00555	CcSEcCtD
Vemurafenib—Myalgia—Bleomycin—melanoma	0.000139	0.00553	CcSEcCtD
Vemurafenib—Back pain—Carmustine—melanoma	0.000137	0.00549	CcSEcCtD
Vemurafenib—Malnutrition—Temozolomide—melanoma	0.000137	0.00548	CcSEcCtD
Vemurafenib—Erythema—Temozolomide—melanoma	0.000137	0.00548	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000137	0.00545	CcSEcCtD
Vemurafenib—Dysgeusia—Temozolomide—melanoma	0.000134	0.00537	CcSEcCtD
Vemurafenib—Anaphylactic shock—Bleomycin—melanoma	0.000133	0.00531	CcSEcCtD
Vemurafenib—Back pain—Temozolomide—melanoma	0.000133	0.0053	CcSEcCtD
Vemurafenib—Infection—Bleomycin—melanoma	0.000132	0.00527	CcSEcCtD
Vemurafenib—Myalgia—Dactinomycin—melanoma	0.000129	0.00516	CcSEcCtD
Vemurafenib—Hypotension—Bleomycin—melanoma	0.000124	0.00496	CcSEcCtD
Vemurafenib—Infection—Dactinomycin—melanoma	0.000123	0.00492	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Bleomycin—melanoma	0.000121	0.00483	CcSEcCtD
Vemurafenib—Myalgia—Carmustine—melanoma	0.000121	0.00483	CcSEcCtD
Vemurafenib—Cough—Temozolomide—melanoma	0.00012	0.00479	CcSEcCtD
Vemurafenib—Weight decreased—Docetaxel—melanoma	0.000119	0.00473	CcSEcCtD
Vemurafenib—Myalgia—Temozolomide—melanoma	0.000117	0.00467	CcSEcCtD
Vemurafenib—Arthralgia—Temozolomide—melanoma	0.000117	0.00467	CcSEcCtD
Vemurafenib—Infestation NOS—Docetaxel—melanoma	0.000117	0.00467	CcSEcCtD
Vemurafenib—Infestation—Docetaxel—melanoma	0.000117	0.00467	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000116	0.00464	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000116	0.00463	CcSEcCtD
Vemurafenib—Decreased appetite—Bleomycin—melanoma	0.000116	0.00461	CcSEcCtD
Vemurafenib—Infection—Carmustine—melanoma	0.000115	0.0046	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Docetaxel—melanoma	0.000115	0.00457	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000113	0.00451	CcSEcCtD
Vemurafenib—Anaphylactic shock—Temozolomide—melanoma	0.000112	0.00448	CcSEcCtD
Vemurafenib—Infection—Temozolomide—melanoma	0.000111	0.00445	CcSEcCtD
Vemurafenib—Nervous system disorder—Temozolomide—melanoma	0.00011	0.00439	CcSEcCtD
Vemurafenib—Skin disorder—Temozolomide—melanoma	0.000109	0.00435	CcSEcCtD
Vemurafenib—Hypotension—Carmustine—melanoma	0.000108	0.00433	CcSEcCtD
Vemurafenib—Decreased appetite—Dactinomycin—melanoma	0.000108	0.0043	CcSEcCtD
Vemurafenib—Fatigue—Dactinomycin—melanoma	0.000107	0.00427	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Carmustine—melanoma	0.000106	0.00422	CcSEcCtD
Vemurafenib—Body temperature increased—Bleomycin—melanoma	0.000105	0.00419	CcSEcCtD
Vemurafenib—Oedema peripheral—Docetaxel—melanoma	0.000103	0.00413	CcSEcCtD
Vemurafenib—Connective tissue disorder—Docetaxel—melanoma	0.000103	0.00412	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Temozolomide—melanoma	0.000102	0.00408	CcSEcCtD
Vemurafenib—Decreased appetite—Carmustine—melanoma	0.000101	0.00403	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Carmustine—melanoma	0.0001	0.004	CcSEcCtD
Vemurafenib—Erythema multiforme—Docetaxel—melanoma	9.92e-05	0.00396	CcSEcCtD
Vemurafenib—Constipation—Carmustine—melanoma	9.92e-05	0.00396	CcSEcCtD
Vemurafenib—Eye disorder—Docetaxel—melanoma	9.81e-05	0.00391	CcSEcCtD
Vemurafenib—Body temperature increased—Dactinomycin—melanoma	9.8e-05	0.00391	CcSEcCtD
Vemurafenib—Hypersensitivity—Bleomycin—melanoma	9.79e-05	0.00391	CcSEcCtD
Vemurafenib—Decreased appetite—Temozolomide—melanoma	9.74e-05	0.00389	CcSEcCtD
Vemurafenib—Cardiac disorder—Docetaxel—melanoma	9.74e-05	0.00389	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Temozolomide—melanoma	9.68e-05	0.00386	CcSEcCtD
Vemurafenib—Fatigue—Temozolomide—melanoma	9.66e-05	0.00386	CcSEcCtD
Vemurafenib—Constipation—Temozolomide—melanoma	9.59e-05	0.00383	CcSEcCtD
Vemurafenib—Asthenia—Bleomycin—melanoma	9.53e-05	0.00381	CcSEcCtD
Vemurafenib—Angiopathy—Docetaxel—melanoma	9.52e-05	0.0038	CcSEcCtD
Vemurafenib—Mediastinal disorder—Docetaxel—melanoma	9.46e-05	0.00378	CcSEcCtD
Vemurafenib—Chills—Docetaxel—melanoma	9.41e-05	0.00376	CcSEcCtD
Vemurafenib—Pruritus—Bleomycin—melanoma	9.4e-05	0.00375	CcSEcCtD
Vemurafenib—Alopecia—Docetaxel—melanoma	9.27e-05	0.0037	CcSEcCtD
Vemurafenib—Body temperature increased—Carmustine—melanoma	9.17e-05	0.00366	CcSEcCtD
Vemurafenib—Erythema—Docetaxel—melanoma	9.13e-05	0.00365	CcSEcCtD
Vemurafenib—Malnutrition—Docetaxel—melanoma	9.13e-05	0.00365	CcSEcCtD
Vemurafenib—Hypersensitivity—Dactinomycin—melanoma	9.13e-05	0.00365	CcSEcCtD
Vemurafenib—Dysgeusia—Docetaxel—melanoma	8.94e-05	0.00357	CcSEcCtD
Vemurafenib—Asthenia—Dactinomycin—melanoma	8.89e-05	0.00355	CcSEcCtD
Vemurafenib—Body temperature increased—Temozolomide—melanoma	8.86e-05	0.00354	CcSEcCtD
Vemurafenib—Back pain—Docetaxel—melanoma	8.83e-05	0.00353	CcSEcCtD
Vemurafenib—Hypersensitivity—Carmustine—melanoma	8.55e-05	0.00341	CcSEcCtD
Vemurafenib—Diarrhoea—Dactinomycin—melanoma	8.48e-05	0.00339	CcSEcCtD
Vemurafenib—Vomiting—Bleomycin—melanoma	8.45e-05	0.00337	CcSEcCtD
Vemurafenib—Rash—Bleomycin—melanoma	8.38e-05	0.00335	CcSEcCtD
Vemurafenib—Dermatitis—Bleomycin—melanoma	8.37e-05	0.00334	CcSEcCtD
Vemurafenib—Asthenia—Carmustine—melanoma	8.32e-05	0.00332	CcSEcCtD
Vemurafenib—Hypersensitivity—Temozolomide—melanoma	8.26e-05	0.0033	CcSEcCtD
Vemurafenib—Asthenia—Temozolomide—melanoma	8.04e-05	0.00321	CcSEcCtD
Vemurafenib—Cough—Docetaxel—melanoma	7.97e-05	0.00318	CcSEcCtD
Vemurafenib—Diarrhoea—Carmustine—melanoma	7.94e-05	0.00317	CcSEcCtD
Vemurafenib—Pruritus—Temozolomide—melanoma	7.93e-05	0.00317	CcSEcCtD
Vemurafenib—Nausea—Bleomycin—melanoma	7.89e-05	0.00315	CcSEcCtD
Vemurafenib—Vomiting—Dactinomycin—melanoma	7.88e-05	0.00315	CcSEcCtD
Vemurafenib—Rash—Dactinomycin—melanoma	7.81e-05	0.00312	CcSEcCtD
Vemurafenib—Arthralgia—Docetaxel—melanoma	7.78e-05	0.0031	CcSEcCtD
Vemurafenib—Myalgia—Docetaxel—melanoma	7.78e-05	0.0031	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	7.72e-05	0.00308	CcSEcCtD
Vemurafenib—Dizziness—Carmustine—melanoma	7.67e-05	0.00306	CcSEcCtD
Vemurafenib—Diarrhoea—Temozolomide—melanoma	7.67e-05	0.00306	CcSEcCtD
Vemurafenib—Anaphylactic shock—Docetaxel—melanoma	7.45e-05	0.00298	CcSEcCtD
Vemurafenib—Dizziness—Temozolomide—melanoma	7.41e-05	0.00296	CcSEcCtD
Vemurafenib—Infection—Docetaxel—melanoma	7.41e-05	0.00296	CcSEcCtD
Vemurafenib—Vomiting—Carmustine—melanoma	7.37e-05	0.00294	CcSEcCtD
Vemurafenib—Nausea—Dactinomycin—melanoma	7.36e-05	0.00294	CcSEcCtD
Vemurafenib—Rash—Carmustine—melanoma	7.31e-05	0.00292	CcSEcCtD
Vemurafenib—Nervous system disorder—Docetaxel—melanoma	7.31e-05	0.00292	CcSEcCtD
Vemurafenib—Dermatitis—Carmustine—melanoma	7.31e-05	0.00292	CcSEcCtD
Vemurafenib—Headache—Carmustine—melanoma	7.27e-05	0.0029	CcSEcCtD
Vemurafenib—Skin disorder—Docetaxel—melanoma	7.24e-05	0.00289	CcSEcCtD
Vemurafenib—Vomiting—Temozolomide—melanoma	7.13e-05	0.00285	CcSEcCtD
Vemurafenib—Rash—Temozolomide—melanoma	7.07e-05	0.00282	CcSEcCtD
Vemurafenib—Dermatitis—Temozolomide—melanoma	7.06e-05	0.00282	CcSEcCtD
Vemurafenib—Headache—Temozolomide—melanoma	7.02e-05	0.0028	CcSEcCtD
Vemurafenib—Hypotension—Docetaxel—melanoma	6.97e-05	0.00278	CcSEcCtD
Vemurafenib—Nausea—Carmustine—melanoma	6.89e-05	0.00275	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Docetaxel—melanoma	6.79e-05	0.00271	CcSEcCtD
Vemurafenib—Nausea—Temozolomide—melanoma	6.66e-05	0.00266	CcSEcCtD
Vemurafenib—Decreased appetite—Docetaxel—melanoma	6.48e-05	0.00259	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Docetaxel—melanoma	6.44e-05	0.00257	CcSEcCtD
Vemurafenib—Fatigue—Docetaxel—melanoma	6.43e-05	0.00257	CcSEcCtD
Vemurafenib—Constipation—Docetaxel—melanoma	6.37e-05	0.00255	CcSEcCtD
Vemurafenib—Body temperature increased—Docetaxel—melanoma	5.89e-05	0.00235	CcSEcCtD
Vemurafenib—Hypersensitivity—Docetaxel—melanoma	5.49e-05	0.00219	CcSEcCtD
Vemurafenib—Asthenia—Docetaxel—melanoma	5.35e-05	0.00214	CcSEcCtD
Vemurafenib—Pruritus—Docetaxel—melanoma	5.27e-05	0.00211	CcSEcCtD
Vemurafenib—Diarrhoea—Docetaxel—melanoma	5.1e-05	0.00204	CcSEcCtD
Vemurafenib—Dizziness—Docetaxel—melanoma	4.93e-05	0.00197	CcSEcCtD
Vemurafenib—Vomiting—Docetaxel—melanoma	4.74e-05	0.00189	CcSEcCtD
Vemurafenib—Rash—Docetaxel—melanoma	4.7e-05	0.00188	CcSEcCtD
Vemurafenib—Dermatitis—Docetaxel—melanoma	4.7e-05	0.00187	CcSEcCtD
Vemurafenib—Headache—Docetaxel—melanoma	4.67e-05	0.00186	CcSEcCtD
Vemurafenib—Nausea—Docetaxel—melanoma	4.43e-05	0.00177	CcSEcCtD
Vemurafenib—CYP3A4—Metabolism—SDHD—melanoma	2.16e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BSG—melanoma	2.16e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CSPG4—melanoma	2.16e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1B—melanoma	2.16e-06	2.55e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MAPK1—melanoma	2.15e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—melanoma	2.15e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ERBB2—melanoma	2.15e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CB—melanoma	2.15e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.15e-06	2.54e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HRAS—melanoma	2.14e-06	2.52e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ERBB2—melanoma	2.13e-06	2.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—melanoma	2.13e-06	2.52e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.13e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CB—melanoma	2.12e-06	2.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—melanoma	2.12e-06	2.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—melanoma	2.11e-06	2.49e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KDR—melanoma	2.1e-06	2.49e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CB—melanoma	2.1e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP1B1—melanoma	2.1e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—melanoma	2.1e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—melanoma	2.1e-06	2.48e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPAM—melanoma	2.09e-06	2.47e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—melanoma	2.08e-06	2.46e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—VCAN—melanoma	2.07e-06	2.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—melanoma	2.06e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP17A1—melanoma	2.06e-06	2.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTNNB1—melanoma	2.04e-06	2.41e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KRAS—melanoma	2.03e-06	2.4e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FN1—melanoma	2.03e-06	2.39e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CG—melanoma	2.02e-06	2.39e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CD—melanoma	2.02e-06	2.39e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1B—melanoma	2.02e-06	2.38e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—melanoma	1.99e-06	2.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1B—melanoma	1.99e-06	2.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CDKN1A—melanoma	1.99e-06	2.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTEN—melanoma	1.99e-06	2.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NOTCH1—melanoma	1.98e-06	2.34e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NFKB1—melanoma	1.98e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CASP3—melanoma	1.98e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1B—melanoma	1.97e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—melanoma	1.97e-06	2.33e-05	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—AKT1—melanoma	1.96e-06	2.32e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.96e-06	2.32e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—melanoma	1.95e-06	2.31e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNA11—melanoma	1.95e-06	2.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD80—melanoma	1.94e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—melanoma	1.94e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APC—melanoma	1.94e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CG—melanoma	1.94e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—NRAS—melanoma	1.94e-06	2.29e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCND1—melanoma	1.92e-06	2.27e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGF—melanoma	1.92e-06	2.26e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—FASN—melanoma	1.91e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CTNNB1—melanoma	1.9e-06	2.25e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.89e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—AKT1—melanoma	1.89e-06	2.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CTNNB1—melanoma	1.88e-06	2.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SLC5A5—melanoma	1.87e-06	2.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PIK3CA—melanoma	1.87e-06	2.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—melanoma	1.87e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CTNNB1—melanoma	1.86e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CDKN1A—melanoma	1.86e-06	2.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK3—melanoma	1.86e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTEN—melanoma	1.86e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.86e-06	2.19e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NFKB1—melanoma	1.85e-06	2.18e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—melanoma	1.84e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CDKN1A—melanoma	1.84e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTEN—melanoma	1.83e-06	2.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—melanoma	1.82e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CDKN1A—melanoma	1.82e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NRAS—melanoma	1.82e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTEN—melanoma	1.82e-06	2.15e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNAQ—melanoma	1.81e-06	2.14e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CD44—melanoma	1.81e-06	2.14e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PLA2G6—melanoma	1.78e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CD—melanoma	1.78e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—melanoma	1.78e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1—melanoma	1.78e-06	2.1e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NRAS—melanoma	1.77e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK1—melanoma	1.77e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—melanoma	1.77e-06	2.09e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CB—melanoma	1.76e-06	2.08e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—melanoma	1.76e-06	2.07e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP17A1—melanoma	1.75e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—melanoma	1.75e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK3—melanoma	1.74e-06	2.06e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP1B1—melanoma	1.74e-06	2.05e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ABCB1—melanoma	1.73e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HRAS—melanoma	1.73e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.72e-06	2.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAP2K1—melanoma	1.72e-06	2.03e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CD—melanoma	1.7e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	1.7e-06	2.01e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK3—melanoma	1.7e-06	2e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—melanoma	1.68e-06	1.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—KRAS—melanoma	1.67e-06	1.97e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—melanoma	1.66e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK1—melanoma	1.66e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NRAS—melanoma	1.66e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—melanoma	1.66e-06	1.96e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNA11—melanoma	1.65e-06	1.95e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—melanoma	1.64e-06	1.94e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NRAS—melanoma	1.64e-06	1.93e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—FGF2—melanoma	1.63e-06	1.93e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—melanoma	1.63e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NRAS—melanoma	1.62e-06	1.92e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—FASN—melanoma	1.61e-06	1.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK1—melanoma	1.61e-06	1.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—melanoma	1.61e-06	1.91e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—VCAN—melanoma	1.6e-06	1.89e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PRKCA—melanoma	1.59e-06	1.88e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SLC5A5—melanoma	1.59e-06	1.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK3—melanoma	1.59e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ERCC2—melanoma	1.58e-06	1.87e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK3—melanoma	1.57e-06	1.85e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—KRAS—melanoma	1.57e-06	1.85e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK3—melanoma	1.55e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CB—melanoma	1.55e-06	1.83e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—melanoma	1.54e-06	1.82e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—melanoma	1.54e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNAQ—melanoma	1.53e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CD44—melanoma	1.53e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—PIK3CA—melanoma	1.53e-06	1.81e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—AKT1—melanoma	1.53e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—melanoma	1.53e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KRAS—melanoma	1.52e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—melanoma	1.52e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTEN—melanoma	1.52e-06	1.8e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—melanoma	1.51e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK1—melanoma	1.51e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—melanoma	1.51e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ERBB2—melanoma	1.51e-06	1.78e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.5e-06	1.77e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK1—melanoma	1.49e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—melanoma	1.49e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.49e-06	1.76e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CB—melanoma	1.49e-06	1.75e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK1—melanoma	1.48e-06	1.75e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—melanoma	1.48e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP1B1—melanoma	1.47e-06	1.74e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PIK3CA—melanoma	1.44e-06	1.7e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ABCB1—melanoma	1.43e-06	1.69e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—melanoma	1.43e-06	1.69e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KRAS—melanoma	1.42e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—HRAS—melanoma	1.42e-06	1.68e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KRAS—melanoma	1.41e-06	1.66e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PIK3CA—melanoma	1.4e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KRAS—melanoma	1.4e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1B—melanoma	1.39e-06	1.65e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—melanoma	1.39e-06	1.64e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CASP3—melanoma	1.37e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—melanoma	1.36e-06	1.61e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—melanoma	1.36e-06	1.6e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP17A1—melanoma	1.35e-06	1.59e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTEN—melanoma	1.34e-06	1.58e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—HRAS—melanoma	1.33e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCND1—melanoma	1.33e-06	1.57e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CTNNB1—melanoma	1.32e-06	1.56e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PRKCA—melanoma	1.32e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PIK3CA—melanoma	1.31e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.31e-06	1.55e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ERCC2—melanoma	1.3e-06	1.54e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.3e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HRAS—melanoma	1.3e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PIK3CA—melanoma	1.29e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—melanoma	1.29e-06	1.53e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CDKN1A—melanoma	1.29e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTEN—melanoma	1.28e-06	1.52e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PIK3CA—melanoma	1.28e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKB1—melanoma	1.28e-06	1.51e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNA11—melanoma	1.27e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—melanoma	1.27e-06	1.5e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—AKT1—melanoma	1.25e-06	1.48e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CG—melanoma	1.25e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—FASN—melanoma	1.25e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—melanoma	1.24e-06	1.47e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SLC5A5—melanoma	1.23e-06	1.45e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—HRAS—melanoma	1.21e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ABCB1—melanoma	1.21e-06	1.43e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—melanoma	1.2e-06	1.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HRAS—melanoma	1.2e-06	1.41e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HRAS—melanoma	1.19e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNAQ—melanoma	1.18e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CD44—melanoma	1.18e-06	1.4e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—AKT1—melanoma	1.17e-06	1.39e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—melanoma	1.16e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—melanoma	1.16e-06	1.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—melanoma	1.15e-06	1.36e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NRAS—melanoma	1.15e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—melanoma	1.15e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—AKT1—melanoma	1.14e-06	1.35e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—melanoma	1.14e-06	1.34e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP1B1—melanoma	1.13e-06	1.34e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PRKCA—melanoma	1.11e-06	1.32e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ERCC2—melanoma	1.11e-06	1.31e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CD—melanoma	1.1e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK3—melanoma	1.1e-06	1.3e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PIK3CA—melanoma	1.07e-06	1.27e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—AKT1—melanoma	1.07e-06	1.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—melanoma	1.07e-06	1.26e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—AKT1—melanoma	1.06e-06	1.25e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—AKT1—melanoma	1.05e-06	1.24e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK1—melanoma	1.04e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—melanoma	1.04e-06	1.23e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CG—melanoma	1.03e-06	1.22e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—melanoma	9.95e-07	1.17e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KRAS—melanoma	9.86e-07	1.16e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CB—melanoma	9.56e-07	1.13e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—melanoma	9.48e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PIK3CA—melanoma	9.45e-07	1.12e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ABCB1—melanoma	9.35e-07	1.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.16e-07	1.08e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CD—melanoma	9.06e-07	1.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PIK3CA—melanoma	9.06e-07	1.07e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—melanoma	8.94e-07	1.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—AKT1—melanoma	8.77e-07	1.04e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—melanoma	8.76e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CG—melanoma	8.73e-07	1.03e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PRKCA—melanoma	8.6e-07	1.02e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ERCC2—melanoma	8.53e-07	1.01e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—melanoma	8.43e-07	9.95e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HRAS—melanoma	8.38e-07	9.9e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTEN—melanoma	8.26e-07	9.76e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—melanoma	8.02e-07	9.47e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CB—melanoma	7.9e-07	9.33e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—melanoma	7.82e-07	9.24e-06	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—AKT1—melanoma	7.72e-07	9.12e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CD—melanoma	7.67e-07	9.06e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—melanoma	7.58e-07	8.95e-06	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—AKT1—melanoma	7.4e-07	8.74e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTEN—melanoma	6.82e-07	8.06e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CG—melanoma	6.74e-07	7.96e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CB—melanoma	6.69e-07	7.9e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—melanoma	6.63e-07	7.83e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—melanoma	6.5e-07	7.68e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CD—melanoma	5.92e-07	7e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—melanoma	5.85e-07	6.91e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PIK3CA—melanoma	5.83e-07	6.89e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTEN—melanoma	5.78e-07	6.83e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CB—melanoma	5.16e-07	6.1e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—melanoma	5.12e-07	6.04e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PIK3CA—melanoma	4.81e-07	5.69e-06	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—AKT1—melanoma	4.76e-07	5.63e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTEN—melanoma	4.46e-07	5.27e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PIK3CA—melanoma	4.08e-07	4.82e-06	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—AKT1—melanoma	3.93e-07	4.64e-06	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—AKT1—melanoma	3.33e-07	3.93e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PIK3CA—melanoma	3.15e-07	3.72e-06	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—AKT1—melanoma	2.57e-07	3.04e-06	CbGpPWpGaD
